Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.
Early trial shows success for daily weight loss pill: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill. Novo Nordisk released data Wednesday showing that patients taking its new medication,
Weight loss pills vs. injections: Which is right for you?
Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and there are fewer restrictions around the timing of the dose than pills. They’re typically only taken once per week, which may be an easier schedule to stick to, especially for people who don’t take many medications regularly.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some psychiatric side effects, new data show.
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
The Weight Loss Hacks That Claim to Work Like Ozempic
Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.
Yahoo4d
Once-a-day weight loss pill shows promise in trial
A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% ...